AKT2 and melanoma: ASO-mediated silencing of exon 10 significantly increased the sensitivity of melanoma cells to PLX4032, suggesting that targeting AKT2 splicing might represent a strategy to overcome MAPKi resistance (Appendix Fig. S11).